

Viread® For Hepatitis B Registration In The Developing World

Approved

1. Argentina	May 2011	21. El Salvador	December 2015	41. Niger	March 2014
2. Armenia	September 2011	22. Ethiopia	August 2015	42. Nigeria	July 2018
3. Aruba	September 2011	23. Gabon	November 2014	43. Pakistan	January 2013
4. Azerbaijan	May 2011	24. Georgia	June 2011	44. Panama	February 2012
5. Bangladesh	June 2011	25. Guatemala	June 2011	45. Paraguay	September 2011
6. Benin	April 2015	26. Guinea	February 2014	46. Peru	June 2011
7. Bhutan	November 2017	27. Guyana	July 2017	47. Philippines	March 2014
8. Bolivia	September 2011	28. Honduras	July 2012	48. Senegal	November 2016
9. Brazil	December 2010	29. Ivory Coast	November 2016	49. Sint Maarten	June 2016
10. Burkina Faso	September 2014	30. Kazakhstan	May 2012	50. South Africa	February 2017
11. Cameroon	January 2016	31. Kenya	September 2014	51. Tanzania	August 2015
12. Central African Republic	January 2015	32. Kyrgyzstan	July 2012	52. Thailand	May 2013
13. Chad	November 2016	33. Madagascar	October 2017	53. Togo	November 2016
14. Chile	November 2011	34. Mali	November 2014	54. Trinidad and Tobago	February 2018
15. Colombia	March 2013	35. Mauritania	November 2016	55. Turkmenistan	April 2014
16. Congo, Republic of the	November 2016	36. Mexico	November 2012	56. Uganda	February 2017
17. Costa Rica	March 2013	37. Moldova	January 2013	57. Ukraine	September 2012
18. Curacao	October 2011	38. Mongolia	September 2014	58. Uruguay	April 2011
19. Dominican Republic	April 2016	39. Namibia	August 2015	59. Uzbekistan	May 2011
20. Egypt	March 2012	40. Nepal	September 2017	60. Zambia	November 2015
				61. Zimbabwe	July 2015

Filed

1. Jamaica	January 2011
2. Malawi	April 2014
3. Venezuela	April 2016

Terms and Definitions

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country.

Filed: Dossier submitted and review pending.

Note

There can be no guarantee that marketing approval for Viread® for the treatment of hepatitis B will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.